Expediting Drug Development for Pediatric Inflammatory Bowel Disease
Andrew E. Mulberg, Harland S. Winter(Massachusetts General Hospital), Anne Robinson(AbbVie (United States)), Athos Bousvaros(Children's Hospital of Wisconsin), Perdita Taylor‐Zapata(National Institute of Child Health), Joel R. Rosh(Cohen Children's Medical Center), Kerry Jo Lee(United States Food and Drug Administration), Shehzad Saeed(Dayton Children's Hospital), Joachim Musaus, Jeffrey S. Hyams(Connecticut Children's Medical Center), Richard B. Colletti(Greenville College), Eric J. Zückerman
Cited by 1
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k